Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bausch + Lomb Corporation stock in Canada

Learn how to buy Bausch + Lomb Corporation stock in 5 easy steps.

Bausch + Lomb Corporation, an eye health company responsible for producing popular contact lens brands like Biotrue and Soflens, is planning to go public. Here's what we know—and how to buy Bausch + Lomb Corporation stock in Canada when it launches.

How to buy Bausch + Lomb Corporation stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BLCO. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners


National Bank Direct Brokerage

  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge

  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers

  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Bausch + Lomb Corporation stock price (NYSE:BLCO)

Use our graph to track the performance of BLCO stocks over time.

Bausch + Lomb Corporation shares at a glance

Information last updated 2022-05-24.
Latest market close$17.94
52-week range$15.90 - $20.20
50-day moving average $17.27
200-day moving average $17.27
Wall St. target price$35.00
PE ratio 33.82
Dividend yield $0 (0%)
Earnings per share (TTM) $0.50

Buy Bausch + Lomb Corporation stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
National Bank Direct Brokerage
Finder Rating:
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
CIBC Investor's Edge
Finder Rating:
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$0 if conditions met, or $100
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
Finder Rating:
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.

Is it a good time to buy Bausch + Lomb Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Bausch + Lomb Corporation price performance over time

Historical closes compared with the close of $17.94 from 2023-05-26

1 week (2023-05-23) -6.22%
1 month (2023-04-28) 2.75%
3 months (2023-03-02) 1.53%
6 months (2022-11-30) 18.57%
1 year (2022-05-27) 1.41%
2 years (2021-05-26) N/A
3 years (2020-05-26) N/A
5 years (2018-05-26) N/A

Is Bausch + Lomb Corporation stock undervalued or overvalued?

Valuing Bausch + Lomb Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bausch + Lomb Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bausch + Lomb Corporation financials

Revenue TTM $3.8 billion
Operating margin TTM 8.38%
Gross profit TTM $2.3 billion
Return on assets TTM 0%
Return on equity TTM 2.16%
Profit margin 4.64%
Book value $20.40
Market capitalisation $5.9 billion

TTM: trailing 12 months

Bausch + Lomb Corporation share dividends

We're not expecting Bausch + Lomb Corporation to pay a dividend over the next 12 months.

Bausch + Lomb Corporation overview

Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site